ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

baxdrostat

Also written as “Baxdrostat”, “CIN-107” and “Baxdrostat/dapagliflozin”.

Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism · Heart Failure · Atherosclerosis, led by 2 companies.

Drug pageBaxdrostat: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 6, 202326 company-led studies, 6 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca256 open or runningphase 3since Sep 6, 2023Aug 17, 2020Dec 10, 2026phase 2 · NCT07222917
Hoffmann-La Rocheits history only10 open or runningphase 1since Nov 20, 2013Nov 20, 2013none ahead

Also a collaborator on its studies: Tigermed Consulting and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 8 earlier studies, Aug 17, 2020 to Aug 12, 2022.

  1. Jul 28, 2021Named baxdrostatINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CIN-107, RO6836191
  2. Jul 3, 20234 phase 1 studies in HypertensionNCT05963009, NCT05961397, NCT05961384 and 1 more
  3. Sep 6, 2023Phase 3 study in HypertensionNCT06034743 · 796 enrolled · United States, Argentina, Australia and more
  4. Dec 5, 2023Phase 3 study in HypertensionNCT06168409 · 218 enrolled · United States, Argentina, Australia and more
  5. Dec 21, 2023Phase 1 study in Healthy ParticipantsNCT06194032 · 28 enrolled · Germany
  6. Feb 13, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06268873 · 2,554 enrolled · United States, Argentina, Australia and more
  7. Mar 22, 2024Phase 2 study in Uncontrolled HypertensionNCT06336356 · 48 enrolled · United States
  8. Mar 27, 2024Phase 3 study in HypertensionNCT06344104 · 326 enrolled · Argentina, Australia, China and more
  9. Apr 5, 2024Phase 1 study in Healthy ParticipantsNCT06357520 · 14 enrolled · United States
  10. Oct 23, 2024Phase 1 study in Healthy ParticipantsNCT06657105 · 22 enrolled · United States
  11. Nov 5, 2024Phase 3 study in Heart FailureNCT06677060 · 11,300 planned · United States, Argentina, Australia and more
  12. Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06742723 · 5,000 planned · United States, Argentina, Australia and more
  13. May 16, 2025Phase 3 study in HyperaldosteronismNCT07007793 · 212 enrolled · United States, Australia, Canada and more
  14. Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicNCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
  15. May 22, 2026Phase 3 study in Uncontrolled HypertensionNCT07686120 · 286 planned · China

Ahead

  1. Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07222917
  2. Jul 27, 2027Primary completion: phase 3 study in HyperaldosteronismNCT07007793
  3. Feb 9, 2028Primary completion: phase 3 study in Uncontrolled HypertensionNCT07686120
  4. Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06268873

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 25 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07686120Uncontrolled Hypertension · China3RecruitingFeb 9, 2028286
NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more2Active, not recruitingDec 10, 2026222
NCT07007793Hyperaldosteronism · United States, Australia, Canada and more3Active, not recruitingJul 27, 2027212
NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingDec 18, 20295,000
NCT06677060Heart Failure · United States, Argentina, Australia and more3RecruitingDec 17, 202911,300
NCT06657105Healthy Participants · United States1CompletedFeb 3, 202522
NCT06357520Healthy Participants · United States1CompletedJun 17, 202414
NCT06344104Hypertension · Argentina, Australia, China and more3CompletedNov 24, 2025326
NCT06336356Uncontrolled Hypertension · United States2CompletedDec 4, 202448
NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingFeb 24, 20282,554
NCT06194032Healthy Participants · Germany1CompletedMay 13, 202428
NCT06168409Hypertension · United States, Argentina, Australia and more3CompletedAug 17, 2025218
NCT06034743Hypertension · United States, Argentina, Australia and more3CompletedMay 21, 2025796
NCT05966324Hypertension · United States1CompletedSep 20, 202241
NCT05963009Hypertension · United States1CompletedApr 29, 202014
NCT05961397Hypertension · United States1CompletedApr 15, 202220
NCT05961384Hypertension · United States1CompletedJan 15, 20228
NCT05526690Hypertension · United States1CompletedDec 12, 202027
NCT05500820Hypertension · United States1CompletedApr 3, 202056
NCT05470725Hypertension · United States1CompletedApr 30, 202133
NCT05432167Renal Insufficiency, Chronic · United States2CompletedMay 2, 2024195
NCT05459688Hypertension · United States2CompletedNov 7, 2023175
NCT05137002Uncontrolled Hypertension · United States2CompletedSep 13, 2022249
NCT04605549Hyperaldosteronism · United States2CompletedOct 28, 202415
NCT04519658Resistant Hypertension · United States2CompletedJun 14, 2022275

How it is read

Names in the registry

  • “Baxdrostat”, 8 entries
  • “CIN-107”, 7 entries
  • “Baxdrostat/dapagliflozin”, 3 entries
  • “baxdrostat”, 3 entries
  • “RO6836191”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.